{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:14:22Z","timestamp":1788243262301,"version":"build-2803163510"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We evaluated the incremental hepatic and metabolic effects of adding sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs), or pioglitazone to comparable background glucose-lowering therapy in Asian adults with type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Embase, the Cochrane Library, and Web of Science through 30 June 2026. Two reviewers independently screened studies, extracted data, and assessed risk of bias. Eligible trials evaluated the addition of a study drug to background glucose-lowering management that was comparable between randomized groups and either remained stable or followed a prespecified adjustment protocol. Changes from baseline in alanine aminotransferase (ALT) and glycated hemoglobin (HbA1c) were coprimary outcomes. Secondary outcomes included aspartate aminotransferase, gamma-glutamyl transferase, magnetic resonance imaging\u2013proton density fat fraction, liver stiffness, fibrosis-4 index, fasting plasma glucose, lipid parameters, body mass index, serum adiponectin, and systolic blood pressure. Random-effects pairwise meta-analyses were performed, and GRADE certainty was assessed for the two coprimary outcomes. Safety outcomes were synthesized narratively because reporting was heterogeneous and frequently incomplete.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included eleven randomized trials: 692 participants were randomized into eligible comparisons, of which 642 participated in the coprimary efficacy analyses. Moderate certainty was found for a reduction in ALT with the addition of an SGLT2 inhibitor compared with background therapy alone (mean difference [MD], \u2212 7.56 U\/L; 95% confidence interval [CI], \u2212 11.24 to \u2212 3.88); however, there was little or no clinically important further benefit observed for HbA1c (MD, \u2212 0.09%; 95% CI, \u2212 0.27 to 0.08; moderate certainty). Modest reductions in ALT were suggested by moderate certainty for GLP-1RAs (MD, \u2212 6.71 U\/L; 95% CI, \u2212 11.53 to \u2212 1.89) while low certainty indicated an HbA1c reduction (MD, \u2212 0.48%; 95% CI, \u2212 0.83 to \u2212 0.14). Secondary exploratory findings favoring add-on therapy existed, although they are unadjusted for multiplicity. The comparative safety could not be assessed reliably.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In short-term randomized trials conducted in Asian study settings, adding SGLT2 inhibitors or GLP-1RAs may improve selected hepatic and metabolic surrogate outcomes. The available evidence does not support a treatment-class ranking, and the durability and clinical significance of these changes remain uncertain because follow-up was short and several comparisons were based on sparse evidence. Comparative safety also remains uncertain because adverse-event reporting was heterogeneous and incomplete.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>\n                      , identifier CRD420251231137.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1942151","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:25:54Z","timestamp":1788240354000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Incremental effects of SGLT2 inhibitors, GLP-1 receptor agonists, and pioglitazone in type 2 diabetes and MASLD across Asian study settings: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Hanwen","family":"Zheng","sequence":"first","affiliation":[{"name":"First Clinical Medical College, Heilongjiang University of Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieru","family":"Han","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Heilongjiang University of Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5691","DOI":"10.7150\/ijbs.117211","article-title":"Pathophysiology, development, and mortality of major non-communicable diseases in metabolic dysfunction-associated steatotic liver disease: a comprehensive review","volume":"21","author":"Kang","year":"2025","journal-title":"Int J Biol Sci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","article-title":"The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes","volume":"22","author":"Younossi","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16016","article-title":"The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes-related and cancer outcomes","volume":"44","author":"Riley","year":"2024","journal-title":"Liver Int"},{"key":"B5","doi-asserted-by":"publisher","first-page":"S1530","DOI":"10.1016\/j.eprac.2026.02.011","article-title":"The role of race and ethnicity in the response to metabolic dysfunction-associated steatotic liver disease treatment: a review","volume":"32","author":"Laurence","year":"2026","journal-title":"Endocr Pract"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2025.101780","article-title":"Ethnic differences in metabolic and histologic features among White, Hispanic, Black and Asian patients with metabolic-associated steatotic liver disease: a network meta-analysis","volume":"30","author":"Lin","year":"2025","journal-title":"Ann Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fgstr.2025.1699508","article-title":"The global landscape of lean metabolic dysfunction-associated steatotic liver disease: insight from Asia and the West","volume":"4","author":"Purnomo","year":"2025","journal-title":"Front Gastroenterol (Lausanne)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101661","article-title":"Impact of SGLT2i and GLP-1RA on liver-related events in patients with MASLD and type 2 diabetes: a network meta-analysis","volume":"8","author":"Li","year":"2025","journal-title":"JHEP Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112137-20250825-02173","article-title":"Chinese expert consensus on multidisciplinary management of type 2 diabetes mellitus complicated with metabolic-dysfunction associated steatotic liver disease (2026 edition)","volume":"106","year":"2026","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.7326\/M23-2788","article-title":"Newer pharmacologic treatments in adults with type 2 diabetes: a clinical guideline from the American College of Physicians","volume":"177","author":"Qaseem","year":"2024","journal-title":"Ann Intern Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3760\/cma.j.cn115791-20241203-00705","article-title":"Guideline for the prevention and treatment of diabetes mellitus in China (2024 edition)","volume":"17","year":"2025","journal-title":"Chin J Diabetes Mellitus"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/eci.70003","article-title":"Pharmacological treatment options for metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus: a systematic review","volume":"55","author":"Konings","year":"2025","journal-title":"Eur J Clin Invest"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13279","article-title":"Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, open-label, three-arm, active control study","volume":"11","author":"Kinoshita","year":"2020","journal-title":"J Diabetes Investig"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2023.108610","article-title":"Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"37","author":"Shi","year":"2023","journal-title":"J Diabetes Complications"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1659740","article-title":"Comparison of the efficacy of antidiabetic agents in type 2 diabetes with MASLD: a network meta-analysis","volume":"16","author":"Shao","year":"2026","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s11901-025-00718-2","article-title":"Efficacy of SGLT2 inhibitors versus GLP-1 receptor agonists in type 2 diabetes patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"25","author":"Elnaggar","year":"2026","journal-title":"Curr Hepatol Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2024.11.017","article-title":"Comparison of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter protein-2 inhibitors on treating metabolic dysfunction-associated steatotic liver disease or metabolic dysfunction-associated steatohepatitis: systematic review and network meta-analysis of randomised controlled trials","volume":"31","author":"Xu","year":"2025","journal-title":"Endocr Pract"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)","volume":"63","author":"Kuchay","year":"2020","journal-title":"Diabetologia"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-03129-6","article-title":"Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials","volume":"21","author":"Deng","year":"2023","journal-title":"BMC Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1182037","article-title":"New anti-diabetic agents for the treatment of non-alcoholic fatty liver disease: a systematic review and network meta-analysis of randomized controlled trials","volume":"14","author":"Kongmalai","year":"2023","journal-title":"Front Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1429","article-title":"Optimally estimating the sample standard deviation from the five-number summary","volume":"11","author":"Shi","year":"2020","journal-title":"Res Synth Methods"},{"key":"B25","article-title":"Chapter 6: Choosing effect measures and computing estimates of effect","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5","author":"Higgins","year":"2024"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0518","article-title":"Comparison of Ipragliflozin and Pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial","volume":"40","author":"Ito","year":"2017","journal-title":"Diabetes Care"},{"key":"B29","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s12876-023-02948-4","article-title":"Effect of empagliflozin and pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial","volume":"23","author":"Attaran","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108487","article-title":"Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: a randomized placebo-controlled trial","volume":"170","author":"Guo","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.109781","article-title":"Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese patients with type 2 diabetes treated by oral anti-diabetic agents: a randomized, clinical trial","volume":"186","author":"Horibe","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2020.01.007","article-title":"Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"44","author":"Zhang","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15580","article-title":"The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease","volume":"36","author":"Phrueksotsai","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31121","article-title":"Multicenter validation of association between decline in MRI-PDFF and histologic response in nonalcoholic steatohepatitis","volume":"72","author":"Loomba","year":"2020","journal-title":"Hepatology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"107647","DOI":"10.1016\/j.phrs.2025.107647","article-title":"The efficacy of sodium-glucose transporter 2 inhibitors in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"213","author":"Li","year":"2025","journal-title":"Pharmacol Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.87802","article-title":"Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement","volume":"308","author":"Piaggio","year":"2012","journal-title":"JAMA"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-S004","article-title":"4. Comprehensive medical evaluation and assessment of comorbidities: Standards of care in diabetes\u20142026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2010.02941.x","article-title":"Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials","volume":"27","author":"DeFronzo","year":"2010","journal-title":"Diabetic Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1102792","article-title":"Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: a GRADE-assessed systematic review and network meta-analysis of randomized controlled trials","volume":"14","author":"Gu","year":"2023","journal-title":"Front Pharmacol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-073725","article-title":"CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials","volume":"381","author":"Junqueira","year":"2023","journal-title":"BMJ"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.769069","article-title":"Efficacy and safety of GLP-1 receptor agonists in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"12","author":"Zhu","year":"2021","journal-title":"Front Endocrinol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101363","article-title":"Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD","volume":"7","author":"Moolla","year":"2025","journal-title":"JHEP Rep"},{"key":"B45","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s00018-024-05507-6","article-title":"GLP-1 and GIP agonism has no direct actions in human hepatocytes or hepatic stellate cells","volume":"81","author":"da Silva Lima","year":"2024","journal-title":"Cell Mol Life Sci"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/metabo15080536","article-title":"SGLT2 inhibitors: multifaceted therapeutic agents in cardiometabolic and renal diseases","volume":"15","author":"Checa-Ros","year":"2025","journal-title":"Metabolites"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15005","article-title":"PPAR-\u03b3-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH","volume":"41","author":"Gastaldelli","year":"2021","journal-title":"Liver Int"},{"key":"B48","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3803\/enm.2024.2193","article-title":"Evolving characteristics of type 2 diabetes mellitus in East Asia","volume":"40","author":"Lee","year":"2025","journal-title":"Endocrinol Metab"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1677517","article-title":"NASH in lean individuals","volume":"39","author":"Younes","year":"2019","journal-title":"Semin Liver Dis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-025-03891-9","article-title":"Visceral adipose tissue area and proportion provide distinct reflections of cardiometabolic outcomes in weight loss; pooled analysis of MRI-assessed CENTRAL and DIRECT PLUS dietary randomized controlled trials","volume":"23","author":"Klein","year":"2025","journal-title":"BMC Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12760","article-title":"No disparity of the efficacy and all-cause mortality between Asian and non-Asian type 2 diabetes patients with sodium-glucose cotransporter 2 inhibitors treatment: a meta-analysis","volume":"9","author":"Cai","year":"2018","journal-title":"J Diabetes Invest"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-2419","article-title":"Efficacy of modern diabetes treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian patients with diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"43","author":"Gan","year":"2020","journal-title":"Diabetes Care"},{"key":"B53","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1146\/annurev.pu.16.050195.000425","article-title":"Ecologic studies in epidemiology: concepts, principles, and methods","volume":"16","author":"Morgenstern","year":"1995","journal-title":"Annu Rev Public Health"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013927","article-title":"Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Liao","year":"2017","journal-title":"BMJ Open"},{"key":"B56","doi-asserted-by":"publisher","first-page":"102111","DOI":"10.1016\/j.clinre.2023.102111","article-title":"Comparison of sodium-glucose cotransporter-2 inhibitors and thiazolidinediones for management of non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"47","author":"Hameed","year":"2023","journal-title":"Clinics Res Hepatol Gastroenterol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001608","article-title":"Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance","volume":"83","author":"Bansal","year":"2026","journal-title":"Hepatology"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"B59","volume-title":"Semaglutide (Wegovy) approved to treat form of liver disease","year":"2026"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1942151\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:25:57Z","timestamp":1788240357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1942151\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":60,"alternative-id":["10.3389\/fendo.2026.1942151"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1942151","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"1942151"}}